Specific human antibodies for selective cancer therapy
US7132510B2 · kind B2 · utility
1Cited by
20References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 31, 2001 |
| Grant date | Nov 7, 2006 |
| Priority date | — |
| Expiry date | Apr 18, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/622
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention is directed to novel peptides and polypeptides that specifically bind to target cells and may have anti-cancer activity, especially blood-related cancers. The present invention includes a peptide or polypeptide comprising an Fv molecule, having a heavy variable chain comprising CDR3, CDR2 and CDR1 regions comprising the amino acid sequences SEQ ID NOS:8, 115 and 114, respectively.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.